Details der Publikation - A phase II study to evaluate safety and immunogenicity of recombinant proteincandidate vaccine against SARS-CoV-2 in adults fully vaccinated against COVID-19 with extension period to evaluate a fourth dose

A phase II study to evaluate safety and immunogenicity of recombinant proteincandidate vaccine against SARS-CoV-2 in adults fully vaccinated against COVID-19 with extension period to evaluate a fourth dose : A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2, in adults fully vaccinated against COVID-19 followed with an extension period to study a fourth dose administration of PHH-1V.

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 09. Jan. Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: SARS-CoV-2 MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02] Phase: Phase 2 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 02-11-2021, Last updated: 2023-01-13

ICTRP ID:	EUCTR2021-005226-26-ES HIPRA-HH-2

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG008063052

Internformat


LEADER	01000caa a22002652 4500
001	CTG008063052
003	DE-627
005	20230425183156.0
007	cr uuu---uuuuu
008	211221s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG008063052
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2021-005226-26-ES
035			\|a (UBBS_Klinische_Studien_WHO)HIPRA-HH-2
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A phase II study to evaluate safety and immunogenicity of recombinant proteincandidate vaccine against SARS-CoV-2 in adults fully vaccinated against COVID-19 with extension period to evaluate a fourth dose \|b A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster vaccination with a recombinant protein RBD fusion dimer candidate (PHH-1V) against SARS-CoV-2, in adults fully vaccinated against COVID-19 followed with an extension period to study a fourth dose administration of PHH-1V.
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 02-11-2021, Last updated: 2023-01-13
650		4	\|a Medical Condition: SARS-CoV-2 MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 09. Jan.
773	1	8	\|g year:2023 \|g day:09 \|g month:01
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-005226-26 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2023 \|b 09 \|c 01

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände